Eli Lilly’s new Pennsylvania build and why it matters for the stock Eli Lilly (LLY) has drawn fresh attention after outlining ...
Eli Lilly is scheduled to report its fourth-quarter results before the market opens Wednesday. Here is what you need to know. PROFIT: Analysts polled by FactSet expect the company to post net income ...
The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key ...
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
Novo Nordisk's stock plummets over 13% after the company warns of potential sales and profit declines in 2026, facing increasing competition in the weight-loss market, particularly from Eli Lilly's ...
Investor's Business Daily on MSN
Pfizer dives; why Lilly's Zepbound still looks like the weight-loss heavyweight
An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.
The diabetes and weight?loss drug market has entered 2026 with extraordinary momentum, building on the explosive growth seen throughout 2025. According to global health information technology ...
Novo Noranisisk A/S shocked investors by forecasting a steep decline in sales this year, a sign of how intensifying price wars in obesity drugs and the Trump administration’s pressure on ...
Novo Nordisk's stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects ...
Novo Nordisk has launched a pill version of its blockbuster weight-loss drug, Wegovy. Novo Nordisk's stock plunged Tuesday ...
By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN, Feb 3 (Reuters) - Wegovy maker Novo Nordisk warned on Tuesday that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results